News

Education and Training Manager Helen Mee reflects on the first of a series of conferences for people with lymphoma

Newer antibody still not recommended in Scotland

Your insight could support a NICE assessment for brentuximab vedotin

We're supporting the MBCV campaign alongside eight blood cancer patient groups.

Our response to the NICE draft decision to reject CAR T-cell technology on the NHS.

Both my husband and his father have had a blood cancer diagnosis so I am concerned whether there is a genetic link. 

Dr Becky Salisbury, our Senior Medical Writer, blogs about one of the hot topics from the recent British Society of Haematology meeting. 

Did you know Lymphoma Action has support groups across the UK? 

Many are organised by our wonderful volunteers and we are looking for more people to help. 

Positive update about ibrutinib and relapsed chronic lymphocytic leukaemia (CLL)

This report from the annual meeting of the British Society of Haematology discusses reducing treatment for Hodgkin lymphoma to reduce side effects. 

After a donor stem cell transplant, Trevor set his sights on the British Transplant Games

Stephen Scowcroft, our Business Development Manager summarises the Lymphoma Coalition Global Summit 2018 held in Prague in July 2018

If you have used Lymphoma TrialsLink, your feedback could help us improve this information service

NICE/NHS England recommend pembrolizumab for people with relapsed or refractory Hodgkin lymphoma who have had brentuximab vedotin and cannot have an autologous stem cell transplant

If you would like to share your views on how cancer care could be improved, Cancer52 would like to hear from you.  

Patients are not involved in MDT meetings as various other cases are discussed, so there is a problem of confidentiality. But talk to your CNS to see whether they could represent your views. 

Our Education and Training Manager, Helen Mee, talks about our upcoming event in Glasgow and explains why you should join us

The British Society of Haematology have published their guidelines on the treatment of chronic lymphocytic leukaemia

Should obinutuzumab be used as part of the first-line treatment of follicular lymphoma or should we stick with rituximab?

It can be difficult knowing you have an illness but are not having treatment - our new information can help.

New guidelines give a clear treatment pathway for people with mantle cell lymphoma

Our Senior Medical Writer, Dr Becky Salisbury, talks about some of the hot topics raised at the recent British Society of Haematology meeting. 

As we celebrate 70 years of the NHS, we say thank you to all the staff who care for people affected by lymphoma. 

Health Information Week is an annual campaign to promote the quality health resources available.

These therapies offer a new treatment option for people with difficult-to-treat B cell lymphomas. 

We look forward to Ropinder joining the organisation in August. 

How good are blood tests at detecting whether lymphoma is progressing or relapsing? We share the answer from issue 103 of Lymphoma Matters magazine. 

Stephen Scowcroft reports back from a biosimilars panel at the European Haematology Association (EHA) Congress 2018. 

Promising results for new antibody treatment for B-cell lymphomas in ongoing Hu5F9-G4 clinical trial

Karen, our regional development manager, and her team of daredevils took on the Velocity Zip Slide in Snowdonia to raise funds for us. 

This Learning Disability Week, we are seeking feedback to help us develop a new version.

New evidence means the targeted drug can now be used routinely on the NHS for more people with classical Hodgkin lymphoma.

Becky, our senior medical writer, shares some of the discussion from the British Society of Haematology annual meeting.

To mark Carers Week 2018 we highlight the support we offer to those caring for someone with lymphoma.

Held at Keble College on 25-26 June, this course is for specialist trainees or consultants. A nurse stream will be held on Sunday 24 June.

To mark Volunteers’ Week (1-7 June), Carly, our new Volunteering Development Manager, tells us more about volunteering with Lymphoma Action.

Lymphoma Canada is seeking the views of peripheral T-cell lymphoma patients who have experience of pralatrexate or belinostat.

Rowan Dartington employee helps secure a grant in her grandmother’s name.

Fancy yourself a bit of a daredevil? Join Team Lymphoma for our Skydive Weekend.

Rachel updates on a successful 16 months of helping people to live with and beyond lymphoma.

Share your experiences in new study from Opinion Health, a UK healthcare research firm. 

To mark International Nurses’ Day on 12 May we say thank you to all the nurses caring for people with lymphoma.

Two of our #TeamLymphoma runners share their experience of running the 2018 London Marathon. 

Lymphoma Canada is seeking the views of DLBCL patients who have had CAR-T Cell therapy. 

Advice on how to regain stamina during recovery and after treatment for lymphoma. 

Learn more about your condition at this year's National Conference. 

Advice for looking after your skin throughout the year, not just when the sun is shining. 

A huge thank you to the 37 runners who took part in the 2018 London Marathon to support Lymphoma Action. 

Jane, a Lymphoma Nurse Clinician, outlines the benefits of attending our National Conference in Manchester on 12 May. 

On April 18 2018 we launched a new name, fresher look, and new website. 

Becky, our senior medical writer, looks at new approaches for high-grade non-Hodgkin lymphoma, discussed at the ASH meeting in December. 

Becky, our senior medical writer, looks at some of the questions raised about maintenance for follicular lymphoma at the post-ASH meeting. 

Becky, our senior medical writer, provides the latest instalment from the 2017 meeting of the American Society of Hematology. 

Becky, our senior medical writer, provides the latest update from the 2017 meeting of the American Society of Hematology. 

NICE recommends obinutuzimab (Gazyvaro) to be considered as part of first-line treatment for advanced follicular lymphoma. 

Initial results from the phase 1/2 LYMRIT-37-01 clinical trial testing betalutin.

Becky, our senior medical writer, provides part one of an update from the 2017 meeting of the American Society of Hematology. 

Initial results from the phase 2 SADAL trial, which has re-opened.

Results from the phase 2 CLARITY clinical trial have informed new treatment groups in the ongoing FLAIR trial.

Ex-pro footballer and Lymphoma Action supporter Tony Lormor shares his top tips for preparing for a challenge event. 

Encouraging results from the first part of the ongoing OASIS clinical trial.

Read our response to The Hidden Cancer: The need to improve blood cancer care. 

Scottish Medicines Consortium chooses not to recommend obinutuzumab for treatment of follicular lymphoma. 

NICE reverses its decision on ibrutinib for relapsed or refractory mantle cell lymphoma. 

As someone who knows what it’s like to live with a lymphoma diagnosis, I am delighted that we have received funding from BUPA UK Foundation to run a programme of Live your Life workshops for young people aged 18-30.

We are delighted to be able to launch our Young People’s Live your Life programme, which will go live with our first workshop in Cambridge on 3 February.

Early results from the phase 1/2 trial of G100 are encouraging.

NICE reverses decision on Ibrutinib and recommends it for baseline commissioning in England. 

'Exceptional' grant to help boost our regional networks and help us reach more people across the UK. 

Kat, a Macmillan Haematology Nurse Specialist, shares how attending our Lymphoma Masterclass helped her focus for the year ahead. 

Brentuximab vedotin recommended as treatment option for systemic anaplastic large cell lymphoma. 

Some people with CLL now able to access venetoclax through Cancer Drugs Fund. 

People with certain mutations (genetic changes) in their lymphoma cells are most likely to benefit.

MOR2018 and lenalidomide could be a new treatment combination for diffuse large B-cell lymphoma (DLBCL) that has relapsed (come back) or was refractory (didn’t respond well) to previous treatment.

New approaches are needed for the treatment of people with T-cell lymphoma after disappointing results in the CHEMO-T trial.

Adding rituximab to chemotherapy improves outcomes for under-18s with advanced-stage B-cell non-Hodgkin lymphoma (NHL)

Recently published findings from the phase 3 RATHL trial (Response-adapted therapy for advanced Hodgkin lymphoma) show that most people can be spared some side effects.